Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Paresthesia 1Neurotoxicity Syndromes 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Breast Neoplasms 1Breast Diseases 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × 2,2'-dithiodiethanesulfonic acid × Clear all
NCT05456256 2026-05-04

HARMONIC

Lantern Pharma Inc.

Phase 2 Recruiting
90 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00039780 2022-07-13

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
764 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Paresthesia, Neurotoxicity Syndromes

NCT00966914 2022-07-13

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
540 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡